Clinical Trials Sponsored by Prolacta Bioscience

Total 1877 results

Prolacta Bioscience

Completed

Safety Study of Human Milk Oligosaccharides in Healthy Adults

Healthy

United States
Prolacta Bioscience

Completed

Dietary Supplement With and Without a Probiotic and/or Antibiotic

Healthy Adults

United States
Prolacta Bioscience

Recruiting

Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation

Hematologic Malignancy

United States
Prolacta Bioscience

Completed

Dietary Supplement With and Without a Probiotic

Healthy Adult Subjects

United States
Prolacta Bioscience

Completed

Evaluation of Prolact-Plus Human Milk Fortifier

Infant, Very Low Birth Weight

United States
Prolacta Bioscience

Terminated

A Study of Safety of PBCLN-003 Following Antibiotic Therapy in Subjects With C.Difficile-associated Diarrhea

Clostridium Difficile Diarrhea

United States
Prolacta Bioscience

Completed

Randomized Study of Human-Milk Based Nutrition Versus Formula in Premature Infants

Infant, Very Low Birth Weight

United States, Austria
Pediatrix
Prolacta Bioscience

Withdrawn

Nutritional Content of Breast Milk From Mothers of Premies

Prematurity | Nutrition

United States
Baylor College of Medicine
Prolacta Bioscience

Completed

Human Milk Cream as a Caloric Supplement in Pre-Term Infants

Prematurity

United States
University of Texas at Austin
Prolacta Bioscience

Unknown

Outpatient Exclusive Human Milk Diet for Single Infant With Complex Congenital Heart Disease

Growth Delay

United States
Emory University
Prolacta Bioscience; Chatham Valley Foundation

Completed

Human Milk for Congenital Gastrointestinal Disorders (HM for CGD)

Congenital Gastrointestinal Disorders

United States
Children's Hospital Medical Center, Cincinnati
Prolacta Bioscience

Completed

Donor Human Milk in Young Children Receiving Bone Marrow Transplantation

Bone Marrow Transplant - Autologous or Allogeneic

United States
Proacta, Incorporated

Terminated

Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States, Taiwan, Singapore, Hong Kong
Proacta, Incorporated

Terminated

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

Lung Cancer

United States
Proacta, Incorporated

Unknown

PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia

Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia

United States
Proacta, Incorporated

Terminated

A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

New Zealand, United States
Proacta, Incorporated

Terminated

Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Canada, New Zealand
Proacta, Incorporated

Completed

PR104 and G-CSF in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States, New Zealand
Proacta, Incorporated

Completed

A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

New Zealand
Proacta, Incorporated

Completed

PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

New Zealand, United States
Anwita Biosciences
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 1 First-in-human Study of JS014

Lymphoma | Solid Tumor, Adult | Neoplasm Malignant | Neoplasm, Experimental

Taiwan
Prolacta Bioscience
Medical University of Vienna; Paracelsus Medical University; Federal University...

Recruiting

Exclusive Human-milk in Preterm NEOnates and Early VASCular Aging Risk Factors (NEOVASC) (NEOVASC)

Prematurity | Vascular Aging

Austria
Profact, Inc.

Terminated

An Outpatient Study Investigating Non-prescription Treatments for COVID-19 (PROFACT-01)

COVID-19

United States
Proacta, Incorporated
National Cancer Institute (NCI)

Completed

PR-104 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of Manitoba
Prolacta Bioscience; Children's Hospital Foundation; Manitoba Developmental Origins...

Completed

Human-derived Human Milk Fortifiers (H2MF), Gut Microbiota and Oxidative Stress in Premature Infants

Premature Birth | Microbial Colonization | Oxidative Stress | Very Low Birth Weight Baby

Canada
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
Shanghai Junshi Bioscience Co., Ltd.
Iqvia Pty Ltd; TopAlliance Biosciences, Inc.

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Advanced Malignancies

United States
Thomas Abrahamsson, MD, PhD
Sahlgrenska University Hospital, Sweden; Region Stockholm; Prolacta Bioscience; Region Uppsala and other collaborators

Active, not recruiting

Human Milk Fortification in Extremely Preterm Infants (N-forte)

Sepsis | Mortality | Necrotizing Enterocolitis

Sweden
Panolos Bioscience

Recruiting

Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent

Metastatic Colorectal Cancer | Hepatocellular Carcinoma | Gastric Cancer | Solid Tumor | Advanced Solid Tumor | Solid Tumor, Adult

Korea, Republic of
ExoRNA Bioscience

Recruiting

The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease

Huntington Disease

China
Dharma Bioscience

Active, not recruiting

Measuring Synovial Fluid Components

Knee Osteoarthritis

Argentina
Ensol Bioscience

Completed

Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects

Healthy

Korea, Republic of
InFlectis BioScience

Active, not recruiting

Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)

Amyotrophic Lateral Sclerosis | ALS

France, Italy
YSOPIA Bioscience

Completed

Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults (CAUSALITY)

Obesity | Metabolic Disease

United States
Altor BioScience

Terminated

QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma

United States
Donesta Bioscience

Completed

Effect of Food on the Bioavailability of 30 mg Estetrol (E4) Tablet in Healthy Postmenopausal Female Volunteers

Food-effect

Bulgaria
Implicit Bioscience

Withdrawn

IC14 in Adult Patients With Dengue Fever

Dengue Fever
Liventa Bioscience

Withdrawn

A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds

Diabetic Foot Ulcers | Wound Care

United States
Altor BioScience

Completed

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Progressive Metastatic Malignancies

United States
Pantarhei Bioscience

Completed

Preoperative Estetrol in Breast Cancer

Breast Cancer

Austria
Pantarhei Bioscience

Completed

Feasibility Study Into the Contraceptive Effect of Estetrol

Healthy

Netherlands
Cosmo Bioscience

Completed

Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma

Prostatic Neoplasms

United States
Implicit Bioscience

Recruiting

IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy

Arrhythmogenic Right Ventricular Dysplasia | Arrhythmogenic Right Ventricular Cardiomyopathy 1 | Arrhythmogenic Left Ventricular Cardiomyopathy | Arrhythmogenic Cardiomyopathy

United States
Hummingbird Bioscience

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Pancreatic Cancer | Non-Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid Tumor

Australia
SN BioScience

Not yet recruiting

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Small-cell Lung Cancer | Pancreas Cancer

Korea, Republic of
Ensol Bioscience

Completed

E1K Intra Articular(IA) Treatment for Knee Osteoarthritis

Osteoarthrosis

Korea, Republic of
Implicit Bioscience

Withdrawn

IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Australia
Altor BioScience

Completed

QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803

Healthy

United States
Implicit Bioscience

Withdrawn

A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome
Crescendo Bioscience

Unknown

Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care

Arthritis, Rheumatoid

United States

Clinical Trials Sponsored by Prolacta Bioscience

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations